Patient-derived T cells genetically engineered to express a chimeric antigen receptor targeting CD1a; upon infusion, CAR signaling (CD3ζ with costimulation) activates cytotoxicity and proliferation to eliminate CD1a-positive T-ALL/LBL cells.
Autologous T cells are genetically engineered to express a chimeric antigen receptor targeting CD1a. Engagement of CD1a on T-ALL/LBL cells triggers CAR signaling (CD3zeta with costimulatory domains), activating proliferation and cytotoxic effector functions (perforin/granzyme release and cytokine secretion) to selectively kill CD1a-positive tumor cells.
YES
DIRECT
Anti-CD1a CAR-T cells bind CD1a and, upon CAR activation (CD3ζ with costimulation), kill targets via cytolytic degranulation (perforin/granzymes) and apoptotic/lytic pathways.
Autologous, lentivirally transduced second-generation CAR T-cell therapy (CD4+ and CD8+) targeting B7-H3 (CD276), EGFR806 epitope on EGFR/EGFRvIII, HER2 (ERBB2), and IL13Rα2 via an IL13-zetakine design; administered locoregionally via intraventricular catheter to drive CAR-mediated cytotoxic killing of CNS tumor cells and mitigate antigen escape.
Autologous CD4+/CD8+ T cells are lentivirally engineered to express four second-generation CARs targeting B7-H3 (CD276), the tumor-restricted EGFR806 epitope on EGFR/EGFRvIII, HER2, and IL13Ra2 (via an IL13-zetakine design). Following locoregional intraventricular delivery, CAR engagement drives antigen-specific T-cell activation, cytokine release, and cytotoxic killing of CNS tumor cells, with multi-antigen targeting intended to mitigate antigen escape.
YES
DIRECT
CAR T cells engineered to recognize B7-H3 bind the antigen on tumor cells and induce cytolysis via T-cell effector functions (perforin/granzyme-mediated apoptosis, with possible Fas/FasL signaling).
Autologous, lentivirally transduced second-generation CAR T-cell therapy (CD4+ and CD8+) targeting B7-H3 (CD276), EGFR806 epitope on EGFR/EGFRvIII, HER2 (ERBB2), and IL13Rα2 via an IL13-zetakine design; administered locoregionally via intraventricular catheter to drive CAR-mediated cytotoxic killing of CNS tumor cells and mitigate antigen escape.
Autologous CD4+/CD8+ T cells are lentivirally engineered to express four second-generation CARs targeting B7-H3 (CD276), the tumor-restricted EGFR806 epitope on EGFR/EGFRvIII, HER2, and IL13Ra2 (via an IL13-zetakine design). Following locoregional intraventricular delivery, CAR engagement drives antigen-specific T-cell activation, cytokine release, and cytotoxic killing of CNS tumor cells, with multi-antigen targeting intended to mitigate antigen escape.
YES
DIRECT
CAR T cells recognizing the EGFR806 epitope on EGFR/EGFRvIII bind target cells and, upon CAR engagement, execute cytolytic killing via perforin/granzyme release and death-receptor pathways.
Autologous, humanized MAGE-A4-directed T-cell receptor-engineered T-cell therapy. Infused T cells recognize MAGE-A4 peptides presented by HLA-A*02 on tumor cells and mediate TCR signaling, cytokine release, and cytotoxic killing.
Autologous T cells are genetically engineered to express a humanized TCR that recognizes MAGE-A4 peptides presented by HLA-A*02 on tumor cells; engagement triggers TCR signaling, cytokine release, expansion, and perforin/granzyme-mediated cytotoxic killing.
NO
INDIRECT
Engineered T cells kill only cells presenting MAGE-A4 peptide bound to HLA-A*02 via TCR engagement, triggering perforin/granzyme cytotoxicity; HLA-A*02 expression alone is not sufficient.
Autologous, lentivirally transduced second-generation CAR T-cell therapy (CD4+ and CD8+) targeting B7-H3 (CD276), EGFR806 epitope on EGFR/EGFRvIII, HER2 (ERBB2), and IL13Rα2 via an IL13-zetakine design; administered locoregionally via intraventricular catheter to drive CAR-mediated cytotoxic killing of CNS tumor cells and mitigate antigen escape.
Autologous CD4+/CD8+ T cells are lentivirally engineered to express four second-generation CARs targeting B7-H3 (CD276), the tumor-restricted EGFR806 epitope on EGFR/EGFRvIII, HER2, and IL13Ra2 (via an IL13-zetakine design). Following locoregional intraventricular delivery, CAR engagement drives antigen-specific T-cell activation, cytokine release, and cytotoxic killing of CNS tumor cells, with multi-antigen targeting intended to mitigate antigen escape.
YES
DIRECT
CAR T cells engineered to recognize HER2 bind HER2 on target cells, triggering T-cell activation and direct killing via perforin/granzyme-mediated cytolysis (and death receptor pathways).